検索対象:     
報告書番号:
※ 半角英数字
 年 ~ 
 年

炭素線誘発異種細胞間バイスタンダー効果の解析

Study on bystander cell-killing effects induced by carbon-ion beams between normal fibroblasts and lung cancer cells

池田 裕子; 横田 裕一郎; 舟山 知夫; 武藤 泰子; 金井 達明*; 小林 泰彦

Ikeda, Hiroko; Yokota, Yuichiro; Funayama, Tomoo; Muto, Yasuko; Kanai, Tatsuaki*; Kobayashi, Yasuhiko

近年、放射線の効果は、照射細胞だけでなく、周辺の照射されていない細胞にも現れる、いわゆるバイスタンダー効果が報告されてきた。本研究では、重粒子線がん治療における腫瘍と正常組織間の応答を明らかにするため、異細胞種間共培養実験下におけるバイスタンダー効果を解析した。実験では、ヒト胎児肺由来正常線維芽細胞株WI-38と、ヒト肺がん細胞株H1299の遺伝子改変株であるH1299/wtp53(正常p53タンパク質を発現)を使用した。炭素線照射(LET=108keV/$$mu$$m, Dose=0.5Gy)又はCo-60 $$gamma$$線照射(LET=0.2keV/$$mu$$m, Dose=0.5Gy)した細胞と、非照射細胞を非接触で6時間又は24時間共培養した後、非照射細胞を回収して、コロニー形成率から生存率を算出した。これまでに、炭素線あるいは$$gamma$$線照射したH1299/wtp53細胞と非照射のWI-38細胞を共培養したとき、WI-38細胞の生存率が増加することを見いだした。この結果から、照射したH1299/wtp53細胞はバイスタンダー細胞の接着や増殖を促進する何らかのシグナル物質を放出している可能性が考えられた。

In this study, we investigated radiation-induced bystander effects between normal fibroblasts and cancer cells to elucidate the responses between normal tissues and tumor in heavy-ion radiotherapy. In our experiments, human lung normal fibroblasts WI-38 line and human lung cancer cells H1299/wtp53 line which is genetically modified to produce normal p53 proteins in their DNA damage response were used. Cells were irradiated with carbon-ion broad beams (LET = 108 keV/$$mu$$m, Dose = 0.5 Gy) or Co-60 $$gamma$$-rays (LET = 0.2 keV/$$mu$$m, Dose = 0.5 Gy), then survival rates of bystander cells after 6- or 24-hours co-culture with irradiated cells were calculated using colony formation assay. It was consequently found that survival rates of non-irradiated WI-38 cells increased when the cells were co-cultured with irradiated H1299/wtp53 cells. From this result, we conclude that some signals are released from irradiated H1299/wtp53 cells to promote cell adhesion and growth of bystander cells.

Access

:

- Accesses

InCites™

:

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.